New drug duo aims to wipe out breast cancer before surgery
NCT ID NCT07307287
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug combination (SHR-A1811 plus pertuzumab) given before surgery to women with early or locally advanced HR-positive, HER2-positive breast cancer. The goal is to see if this treatment can eliminate all cancer cells in the breast and lymph nodes by the time of surgery. About 30 women will take part, and the study will also monitor side effects and long-term outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers
- Could a diabetes drug slow breast cancer growth?
- Could Pre-Surgery radiation make inoperable breast tumors removable?
- Young breast cancer patients share views on fertility risks in new survey
- New precision approach aims to wipe out breast cancer before surgery
- Freezing tumors to supercharge immunotherapy: new hope for aggressive breast cancer?